Antiviral drug

TNO Study Shows Efficacy of Corona Canon Against Covid-19

Retrieved on: 
Friday, June 4, 2021

RIJSWIJK, Netherlands, June 4, 2021 /PRNewswire/ --The Scalene Hypercharge Corona Canon (Shycocan) can be used effectively to neutralize Covid-19 and other corona viruses in closed spaces.

Key Points: 
  • RIJSWIJK, Netherlands, June 4, 2021 /PRNewswire/ --The Scalene Hypercharge Corona Canon (Shycocan) can be used effectively to neutralize Covid-19 and other corona viruses in closed spaces.
  • Research by TNO1shows that the corona canon reduces the SARS COV-2 virus on stainless steel surfaces by 94.9 percent within fifteen minutes.
  • In the Netherlands, some schools, hair salons and a funeral home are already working with the corona canon.
  • That is why we are pleased that TNO has successfully demonstrated the antiviral effect of the Shycocan," says Jongbloed.

PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals

Retrieved on: 
Tuesday, June 1, 2021

PharmaTher and TSRL share the commitment to commercialize a patented hydrogel-forming microneedle patch delivery technology licensed from Queens University of Belfast.

Key Points: 
  • PharmaTher and TSRL share the commitment to commercialize a patented hydrogel-forming microneedle patch delivery technology licensed from Queens University of Belfast.
  • Zanamivir, other antiviral therapeutics and vaccines) in a microneedle patch with the potential to improve on the safety (i.e.
  • TSRL has successfully conducted a pre-IND meeting with the US FDA and achieved agreement with the agency on their proposed 505(b)2 product development plans.
  • PharmaTher is currently conducting an FDA approved phase 2 clinical study with ketamine to treat Parkinsons disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics.

Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19

Retrieved on: 
Wednesday, May 26, 2021

This includes, for example, individuals who are 65 years of age and older or individuals who have certain medical conditions.

Key Points: 
  • This includes, for example, individuals who are 65 years of age and older or individuals who have certain medical conditions.
  • "It is important to expand the arsenal of monoclonal antibody therapies that are expected to retain activity against the circulating variants of COVID-19 in the United States."
  • Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful antigens such as viruses.
  • The FDA is carefully monitoring circulating viral variants and their sensitivity to monoclonal antibodies authorized to treat COVID-19, including sotrovimab.

Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Progresses to Stage 2 of SARS-CoV-2 Antiviral Screening Program at CSIRO

Retrieved on: 
Thursday, May 20, 2021

b'SYDNEY, Australia, May 20, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, today announced further results for the Company\xe2\x80\x99s synthetic anti-infective R327, as part of the SARS-CoV-2 Antiviral Screening Program (the Program).

Key Points: 
  • b'SYDNEY, Australia, May 20, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, today announced further results for the Company\xe2\x80\x99s synthetic anti-infective R327, as part of the SARS-CoV-2 Antiviral Screening Program (the Program).
  • \xe2\x80\x9cWe are keen to continue our work with CSIRO in Stage 2 of the Anti-Viral Screening Program.\xe2\x80\x9d\nThe further Stage 1B testing which was highlighted as necessary in the Company\xe2\x80\x99s 12 February 2021 announcement has now been conducted by the Doherty Institute as part of the Program budget.
  • All intellectual property rights are retained by the Company with data to be reported as it becomes available.
  • Recce\xe2\x80\x99s anti-infective pipeline seeks to exploit the unique capabilities of RECCE\xc2\xae technologies targeting synergistic, unmet medical needs.\n'

Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors

Retrieved on: 
Thursday, May 20, 2021

b'BOSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Directors.

Key Points: 
  • b'BOSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Directors.
  • With AT-527, Atea has the potential to bring an easily administered oral antiviral to help in the fight against this global public health crisis.
  • I am looking forward to lending my expertise to help advance this important program, while also supporting Atea in the development of its broader antiviral pipeline for severe viral diseases,\xe2\x80\x9d commented Dr. Adams.\nDr.
  • Before beginning his public service in 2014, Dr. Adams was a practicing anesthesiologist and Associate Professor in the Department of Anesthesiology at Indiana University.

CURE Pharmaceutical First Quarter Revenue Quadruples to $1.5 million; Company Expands Clinical Pipeline to Include Psychedelics

Retrieved on: 
Monday, May 17, 2021

The other will explore the application of a known anti-seizure API to treat adult and pediatric patients who suffer from its debilitating effects.

Key Points: 
  • The other will explore the application of a known anti-seizure API to treat adult and pediatric patients who suffer from its debilitating effects.
  • As part of our recently announced psychedelic and antiviral clinical development, these programs are exciting because they leverage existing safety and toxicity data.
  • We believe this will allow us to more quickly develop orally bioavailable treatments and expand our specialty pharmaceutical pipeline.
  • The forward-looking statements in this press release reflect CURE\xe2\x80\x99s judgment as of the date of this press release.

Independent Data Safety Monitoring Board Recommends Appili Therapeutics Complete Its Phase 3 Avigan®/Reeqonus™ Trial for Mild-to-Moderate COVID-19 Patients

Retrieved on: 
Monday, May 17, 2021

The DSMB reported no safety issues that would have required the study to be terminated.

Key Points: 
  • The DSMB reported no safety issues that would have required the study to be terminated.
  • As a result, Appili will continue the study without modification.\nThe interim analysis is based on data from approximately 600 subjects.
  • Participants self-administer the drug regimen in their homes, with clinical investigators monitoring them remotely.\nAvigan/Reeqonusis a broad-spectrum antiviral in oral tablet form.
  • These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.

Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 17, 2021

\xe2\x80\x9cAs discussed in our coronavirus update release earlier this month, we continue developing novel SARS-CoV-2 oral protease inhibitors and are rapidly advancing lead compounds.

Key Points: 
  • \xe2\x80\x9cAs discussed in our coronavirus update release earlier this month, we continue developing novel SARS-CoV-2 oral protease inhibitors and are rapidly advancing lead compounds.
  • That agreement provides Cocrystal with an exclusive, royalty-bearing license to develop and commercialize therapeutic, diagnostic and prophylactic products against coronaviruses, caliciviruses and picornaviruses based on antivirals discovered by KSURF.
  • The Company believes the 3CL protease has the ability to convert the inactive SARS-CoV-2 replication enzymes into the active form.
  • As anticipated, Cocrystal reported no revenues for the first quarter of 2021 compared with $461,000 in revenues for the first quarter of 2020.

Researchers Show How COVID-19 Virus Triggers Immune Signaling "Storm"

Retrieved on: 
Friday, May 14, 2021

The virus evolved to have a protein spike that snags ACE2 as the first step in invading human lung cells, where the virus multiplies.

Key Points: 
  • The virus evolved to have a protein spike that snags ACE2 as the first step in invading human lung cells, where the virus multiplies.
  • Accordingly, all approved COVID-19 antiviral drugs and vaccines work by interfering with, or protecting against, this viral spike/ACE2 interaction.\nMounting evidence, however, suggests that the virus also interacts directly with human immune cells, which have little ACE2 on their surfaces.
  • Five were C-type lectins, carbohydrate-binding protein units with many biological functions, including in immune defenses.
  • Nanobodies are smaller derivatives of antibodies, immune proteins that form a surveillance system by recognizing invading microbes.

ILC Therapeutics Announces Board Changes and Funding Round to Accelerate Covid-19 Drug

Retrieved on: 
Thursday, May 13, 2021

In some cases (SARS, MERS, Covid-19), viruses can evade the interferon response by delaying the innate immune response.

Key Points: 
  • In some cases (SARS, MERS, Covid-19), viruses can evade the interferon response by delaying the innate immune response.
  • A therapeutic like Alfacyte\xe2\x84\xa2 can offer enhanced interference to Covid-19 replication in the body and activate the body\xe2\x80\x99s own Natural Killer (NK) cells to fight virus infection.
  • Alfacyte\xe2\x84\xa2 has the potential to become an important antiviral treatment in the ongoing fight against RVI\xe2\x80\x99s in general and Covid-19 in particular.
  • It is also a vital treatment for those who are not able to take vaccines or choose not to.